Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...

For example the Biogen Inc. (NASDAQ:BIIB) share price dropped 56% over five years. That's an unpleasant experience for long term holders. And it's not just long term holders hurting, because the stock ...

Shares of Biogen Inc. BIIB shed 1.11% to $136.84 Monday, on what proved to be an all-around favorable trading session for the ...

American Century Companies Inc. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 46.8% during the fourth quarter, according to its most recent filing with the Securities ...

The company and Sanofi just posted positive results from a pivotal ADEPT Phase 2/3 trial. While we’re not seeing any specific news, BIIB has become a value play. Keep your portfolio well-protected ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz, Mizuho Securities ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...